Collegium Pharmaceutical (COLL) Expected to Announce Quarterly Earnings on Thursday

Key Points

• Collegium Pharmaceutical is expected to announce its Q2 2025 earnings on August 7th, with analysts predicting earnings of $1.88 per share and revenue of $182.26 million.
• The company recently authorized a stock buyback plan to repurchase up to $150 million worth of shares, which signals confidence in the company's valuation.
• Collegium's stock has a current market cap of $986.39 million and a 52-week stock price range between $23.23 and $42.29.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) is expected to be posting its Q2 2025 quarterly earnings results before the market opens on Thursday, August 7th. Analysts expect Collegium Pharmaceutical to post earnings of $1.88 per share and revenue of $182.26 million for the quarter. Collegium Pharmaceutical has set its FY 2025 guidance at EPS.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The specialty pharmaceutical company reported $1.49 EPS for the quarter, missing the consensus estimate of $1.50 by ($0.01). The firm had revenue of $177.76 million during the quarter, compared to the consensus estimate of $174.96 million. Collegium Pharmaceutical had a net margin of 6.61% and a return on equity of 99.08%. The company's quarterly revenue was up 22.7% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.45 EPS. On average, analysts expect Collegium Pharmaceutical to post $6 EPS for the current fiscal year and $6 EPS for the next fiscal year.

Collegium Pharmaceutical Stock Up 0.7%

COLL traded up $0.21 during midday trading on Friday, hitting $30.07. 445,406 shares of the company's stock traded hands, compared to its average volume of 267,959. The company has a debt-to-equity ratio of 3.30, a current ratio of 1.08 and a quick ratio of 1.01. The company has a market cap of $966.15 million, a PE ratio of 24.65 and a beta of 0.68. The stock's fifty day simple moving average is $30.48 and its 200-day simple moving average is $29.68. Collegium Pharmaceutical has a one year low of $23.23 and a one year high of $42.29.

Collegium Pharmaceutical announced that its board has initiated a stock repurchase plan on Monday, July 7th that allows the company to repurchase $150.00 million in shares. This repurchase authorization allows the specialty pharmaceutical company to reacquire up to 15.4% of its shares through open market purchases. Shares repurchase plans are generally an indication that the company's management believes its shares are undervalued.

Analyst Ratings Changes

Several analysts have recently issued reports on the company. Needham & Company LLC reiterated a "buy" rating and set a $46.00 price target on shares of Collegium Pharmaceutical in a research note on Wednesday, April 9th. Wall Street Zen cut shares of Collegium Pharmaceutical from a "strong-buy" rating to a "buy" rating in a research note on Saturday, July 5th. Finally, Piper Sandler reiterated a "neutral" rating and issued a $37.00 target price (up from $36.00) on shares of Collegium Pharmaceutical in a research note on Friday, May 9th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $43.75.

Insider Buying and Selling

In other news, Director John Gordon Freund sold 6,601 shares of the company's stock in a transaction that occurred on Monday, June 9th. The stock was sold at an average price of $30.62, for a total transaction of $202,122.62. Following the completion of the transaction, the director directly owned 70,658 shares in the company, valued at $2,163,547.96. The trade was a 8.54% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 2.51% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Collegium Pharmaceutical

Several large investors have recently bought and sold shares of the stock. Millennium Management LLC grew its position in Collegium Pharmaceutical by 248.5% in the 1st quarter. Millennium Management LLC now owns 647,832 shares of the specialty pharmaceutical company's stock worth $19,338,000 after purchasing an additional 461,914 shares during the last quarter. Jane Street Group LLC grew its position in Collegium Pharmaceutical by 218.7% during the first quarter. Jane Street Group LLC now owns 131,520 shares of the specialty pharmaceutical company's stock worth $3,926,000 after buying an additional 90,255 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in Collegium Pharmaceutical by 7.0% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 71,014 shares of the specialty pharmaceutical company's stock valued at $2,120,000 after acquiring an additional 4,625 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in Collegium Pharmaceutical by 4.5% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 19,046 shares of the specialty pharmaceutical company's stock valued at $569,000 after acquiring an additional 825 shares in the last quarter.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.